About
Cellectar Biosciences develops targeted cancer therapies using its Phospholipid Drug Conjugate (PDC) platform to deliver therapeutic agents, including radioisotopes and cytotoxins, directly to tumor cells to maximize efficacy and minimize off-target effects.
Explore Cellectar Biosciences, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.